DE122007000051I1 - Kristallmodifikation von 1-(2,6-Difluorbenzyl)-1H-1,2,3,Triazol-4-Carbons{ureamid und seine Verwendung als Antiepileptikum - Google Patents

Kristallmodifikation von 1-(2,6-Difluorbenzyl)-1H-1,2,3,Triazol-4-Carbons{ureamid und seine Verwendung als Antiepileptikum

Info

Publication number
DE122007000051I1
DE122007000051I1 DE200712000051 DE122007000051C DE122007000051I1 DE 122007000051 I1 DE122007000051 I1 DE 122007000051I1 DE 200712000051 DE200712000051 DE 200712000051 DE 122007000051 C DE122007000051 C DE 122007000051C DE 122007000051 I1 DE122007000051 I1 DE 122007000051I1
Authority
DE
Germany
Prior art keywords
ureamide
antiepileptic
difluorobenzyl
triazole
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE200712000051
Other languages
English (en)
Other versions
DE122007000051I2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000051(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE122007000051I1 publication Critical patent/DE122007000051I1/de
Publication of DE122007000051I2 publication Critical patent/DE122007000051I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
DE122007000051C 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl) -1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum Active DE122007000051I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
PCT/EP1998/003427 WO1998056772A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Publications (2)

Publication Number Publication Date
DE122007000051I1 true DE122007000051I1 (de) 2007-11-08
DE122007000051I2 DE122007000051I2 (de) 2009-02-19

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69811500T Expired - Lifetime DE69811500T2 (de) 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
DE122007000051C Active DE122007000051I2 (de) 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl) -1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
DE69813560T Expired - Lifetime DE69813560T2 (de) 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69811500T Expired - Lifetime DE69811500T2 (de) 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69813560T Expired - Lifetime DE69813560T2 (de) 1997-06-10 1998-06-08 Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum

Country Status (37)

Country Link
US (6) US6740669B1 (de)
EP (2) EP0994863B1 (de)
JP (2) JP3672574B2 (de)
KR (2) KR100425656B1 (de)
CN (3) CN1132820C (de)
AR (4) AR012945A1 (de)
AT (2) ATE237599T1 (de)
AU (2) AU725517B2 (de)
BR (2) BR9804947A (de)
CA (3) CA2256015C (de)
CO (2) CO4940448A1 (de)
CY (1) CY2007014I1 (de)
CZ (2) CZ292481B6 (de)
DE (3) DE69811500T2 (de)
DK (2) DK0994863T3 (de)
ES (2) ES2192779T3 (de)
FR (1) FR07C0037I2 (de)
HK (3) HK1028242A1 (de)
HU (2) HU226107B1 (de)
ID (2) ID27660A (de)
IL (2) IL125733A (de)
LU (1) LU91345I2 (de)
MY (2) MY120156A (de)
NL (1) NL300284I2 (de)
NO (2) NO329315B1 (de)
NZ (2) NZ331371A (de)
PE (2) PE80999A1 (de)
PL (2) PL191943B1 (de)
PT (1) PT994864E (de)
RU (2) RU2194041C2 (de)
SI (2) SI0994863T1 (de)
SK (2) SK283685B6 (de)
TR (2) TR199801630T1 (de)
TW (2) TW403740B (de)
UY (1) UY25844A1 (de)
WO (2) WO1998056773A1 (de)
ZA (2) ZA984966B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
ATE390425T1 (de) * 2002-05-31 2008-04-15 Schering Corp Xanthin-phosphodiesterase-v-hemmer polymorphe
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
WO2010043849A1 (en) * 2008-10-13 2010-04-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) * 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate
EP2465853A1 (de) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph von Rufinamid und Verfahren zu seiner Herstellung
ITMI20110718A1 (it) * 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
WO2014013511A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (fi) 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP2550456B2 (ja) 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1072215C (zh) 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
KR100481137B1 (ko) * 1996-07-11 2005-04-08 노파르티스 아게 1-치환 4-시아노-1,2,3-트리아졸의 제조방법
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
CA2256015C (en) 2008-06-03
PT994864E (pt) 2003-07-31
AR012945A1 (es) 2000-11-22
KR100409168B1 (ko) 2004-01-31
DE122007000051I2 (de) 2009-02-19
KR19990087836A (ko) 1999-12-27
HUP0000798A2 (hu) 2000-10-30
TW403740B (en) 2000-09-01
CY2007014I2 (el) 2009-11-04
RU2194041C2 (ru) 2002-12-10
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
CZ253498A3 (cs) 1999-04-14
DK0994863T3 (da) 2003-05-26
FR07C0037I2 (de) 2008-05-16
HK1028242A1 (en) 2001-02-09
US6455556B2 (en) 2002-09-24
US7750028B2 (en) 2010-07-06
NO983666L (no) 1998-12-17
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
SI0994863T1 (en) 2003-08-31
ES2192779T3 (es) 2003-10-16
EP0994863B1 (de) 2003-02-19
DK0994864T3 (da) 2003-07-21
CZ292481B6 (cs) 2003-09-17
NO329315B1 (no) 2010-09-27
EP0994863A1 (de) 2000-04-26
LU91345I2 (fr) 2007-09-04
NL300284I2 (nl) 2007-11-01
SK283685B6 (sk) 2003-12-02
JP3672574B2 (ja) 2005-07-20
ATE232852T1 (de) 2003-03-15
FR07C0037I1 (de) 2007-08-17
TR199801630T1 (xx) 1999-06-21
AU725528B2 (en) 2000-10-12
CN1217716A (zh) 1999-05-26
CN1132820C (zh) 2003-12-31
PL191943B1 (pl) 2006-07-31
NO983667L (no) 1998-12-17
BR9804946A (pt) 1999-08-24
EP0994864B1 (de) 2003-04-16
CA2256013A1 (en) 1998-12-17
IL125732A0 (en) 1999-04-11
NZ331371A (en) 2000-08-25
US20010037029A1 (en) 2001-11-01
HU226107B1 (en) 2008-04-28
CN1298708C (zh) 2007-02-07
NO329314B1 (no) 2010-09-27
CZ292260B6 (cs) 2003-08-13
AR012946A1 (es) 2000-11-22
US20060116520A1 (en) 2006-06-01
AU725517B2 (en) 2000-10-12
CA2614926A1 (en) 1998-12-17
TR199801631T1 (xx) 1999-06-21
CO4940448A1 (es) 2000-07-24
EP0994864A1 (de) 2000-04-26
IL125732A (en) 2002-12-01
CA2256013C (en) 2007-10-16
ES2197485T3 (es) 2004-01-01
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
CN1159300C (zh) 2004-07-28
AR061005A2 (es) 2008-07-30
US8076362B2 (en) 2011-12-13
CZ253398A3 (cs) 1999-04-14
ATE237599T1 (de) 2003-05-15
MY125854A (en) 2006-08-30
MY120156A (en) 2005-09-30
CN1259127A (zh) 2000-07-05
PL330798A1 (en) 1999-06-07
NZ331370A (en) 2000-08-25
ZA984967B (en) 1999-01-11
US20100310655A1 (en) 2010-12-09
US20040167186A1 (en) 2004-08-26
JP2000516259A (ja) 2000-12-05
ID21014A (id) 1999-04-08
KR19990087835A (ko) 1999-12-27
JP2000516258A (ja) 2000-12-05
HUP0000798A3 (en) 2000-10-30
PE80999A1 (es) 1999-09-06
US20030125568A1 (en) 2003-07-03
TW526195B (en) 2003-04-01
IL125733A0 (en) 1999-04-11
DE69811500D1 (de) 2003-03-27
AR061004A2 (es) 2008-07-30
BR9804947A (pt) 1999-08-24
HUP0002113A3 (en) 2002-09-30
KR100425656B1 (ko) 2004-05-17
AU8437298A (en) 1998-12-30
UY25844A1 (es) 2001-08-27
DE69813560D1 (de) 2003-05-22
LU91345I9 (de) 2018-12-31
SK109498A3 (en) 1998-12-02
PL330764A1 (en) 1999-05-24
CO4940452A1 (es) 2000-07-24
PL192114B1 (pl) 2006-08-31
WO1998056772A1 (en) 1998-12-17
CA2256015A1 (en) 1998-12-17
IL125733A (en) 2002-12-01
SI0994864T1 (en) 2003-10-31
DE69813560T2 (de) 2004-02-05
HU225153B1 (en) 2006-07-28
RU2198167C2 (ru) 2003-02-10
JP3672575B2 (ja) 2005-07-20
HK1028241A1 (en) 2001-02-09
NO983666D0 (no) 1998-08-11
CA2614926C (en) 2010-02-09
CN1572789A (zh) 2005-02-02
SK109398A3 (en) 1998-12-02
ID27660A (id) 2001-04-19
DE69811500T2 (de) 2004-04-01
ZA984966B (en) 1999-01-11
US6740669B1 (en) 2004-05-25
HUP0002113A2 (hu) 2001-02-28
PE79799A1 (es) 1999-09-03
HK1028031A1 (en) 2001-02-02

Similar Documents

Publication Publication Date Title
DE122007000051I1 (de) Kristallmodifikation von 1-(2,6-Difluorbenzyl)-1H-1,2,3,Triazol-4-Carbons{ureamid und seine Verwendung als Antiepileptikum
DE69024556T2 (de) Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
DE122007000020I2 (de) Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwendung als pharmazeutische metallchelatoren
DE59403814D1 (de) Substituierte Triazolinone sowie ihre Verwendung als Herbizide
DE69629670D1 (de) Lactam-enthaltende hydroxamsäure-derivate, deren herstellung und deren verwendung als inhibitoren von matrix-metalloproteasen
DE59608154D1 (de) Verwendung von polyasparaginsäureamiden als lederhilfsmittel
ATE232207T1 (de) N-triazolyl-2-indolcarbonsäureamide und ihre verwendung als cck-a agonisten
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE69616944D1 (de) Verwendung von des-aspartat-angiotensin i als wirkstoff gegen herzhypertrophie
ATE271313T1 (de) Verwendung von pyrrolverbindungen als antifouling-wirkstoff
ATE181071T1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
DE69421235T2 (de) Amidrazone und ihre Verwendung als Pestizide
DE59407240D1 (de) Substituierte azadioxacycloalkene und ihre verwendung als fungizide
DE69418001D1 (de) Hydrazin-Derivate und ihre Verwendung als Insektizide
DE69505124D1 (de) Verwendung von dibutylmalat als insektenlockstoff
DE59610382D1 (de) Halogenbenzimidazole und ihre verwendung als mikrobizide
DE1229027T1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide
DE69616760D1 (de) Verwendung von 4-tert-butyl-1-cyclohexanol als antioxidant
TH9801002100B (th) รูปแบบโครงสร้างผลึกดัดแปลงของ 1-(2,6-ไดฟลูออโรเบนซิล)-1h-1,2,3-ไตรอาโซล-4-คาร์บอกซาไมด์
TR199800920A2 (xx) Transjenik insan d��� hayvanlardan kopyalama komplekslerinin safla�t�r�lmas�.
ATE218343T1 (de) Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
DE59912335D1 (de) Verwendung von tricyclischen aldehyden als riechstoffe
DE59408603D1 (de) Substituierte Triazolinone sowie ihre Verwendung als Herbizide
DE69738396D1 (de) Verwendung von gaba-aufnahme-inhibitoren als mittel gegen husten